nach oben

26.04.2024 | Review Article

Potential Single Nucleotide Polymorphisms markers for radiation dermatitis in head and neck cancer patients: a meta-analysis

verfasst von: Beatriz Regina Lima Aguiar, Elaine Barros Ferreira, Ana Gabriela Costa Normando, Sabrina dos Santos Dias, Eliete Neves Silva Guerra, Paula Elaine Diniz Reis, PhD

Erschienen in: Strahlentherapie und Onkologie

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To identify potential Single Nucleotide Polymorphisms (SNPs) of susceptibility for the development of acute radiation dermatitis in head and neck cancer patients, and also to verify the association between SNPs and the severity of RD.

Methods

This systematic review was reported according to the PRISMA guideline. The proportion meta-analysis was performed to identify the prevalence of genetic markers by geographical region and radiation dermatitis severity. The meta-analysis was performed to verify the association between genetic markers and RD severity. The certainty of the evidence was assessed by GRADE.

Results

Thirteen studies were included. The most prevalent SNPs were XRCC3 (rs861639) (36%), TGFβ1 (rs1800469) (35%), and RAD51 (rs1801321) (34%). There are prevalence studies in Europe and Asia, with a similar prevalence for all SNPs (29–40%). The prevalence was higher in patients who developed radiation dermatitis ≤2 for any subtype of genes (75–76%). No SNP showed a statistically significant association with very low certainty of evidence.

Conclusion

The most prevalent SNPs may be predictors of acute RD. The analysis of SNP before starting radiation therapy may be a promising method to predict the risk of developing radiation dermatitis and allow radiosensitive patients to have a customized treatment. This current review provides new research directions.

Nur mit Berechtigung zugänglich

Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandi JR (2020) Head and neck squamous cell carcinoma. Nat Rev Dis Primers 6:92. https://doi.org/10.1038/s41572-020-00224-3CrossRefPubMedPubMedCentral

Ferlay J. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer, https://gco.iarc.fr/today [accessed 18 September 2021].

Sung H, Ferlay J, Siegel RL et al (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 71:209–249. https://doi.org/10.3322/caac.21660CrossRefPubMed

Alfouzan AF (2021) Radiation therapy in head and neck cancer. Saudi Med J 42:247–254. https://doi.org/10.15537/smj.2021.42.3.20210660CrossRefPubMedPubMedCentral

Brook I (2021) Early side effects of radiation treatment for head and neck cancer. Cancer Radiother 25:507–513. https://doi.org/10.1016/j.canrad.2021.02.001CrossRefPubMed

Manier KK, Rowe LS, Welsh J, Armstrong TS (2018) The impact and incidence of altered body image in patients with head and neck tumors: a systematic review. Neurooncol Pract 5:204–213. https://doi.org/10.1093/nop/npy018CrossRefPubMedPubMedCentral

Wei J, Meng L, Hou X et al (2019) Radiation-induced skin reactions: mechanism and treatment. Cancer Manag Res 11:167–177. https://doi.org/10.2147/cmar.s188655CrossRefPubMed

Melissant HC, Jansen F, Eerenstein SE et al (2021) Body image distress in head and neck cancer patients: what are we looking at? Support Care Cancer 29:2161–2169. https://doi.org/10.1007/s00520-020-05725-1CrossRefPubMed

Ferreira EB, Vasques CI, Gadia R et al (2017) Topical interventions to prevent acute radiation dermatitis in head and neck cancer patients: a systematic review. Support Care Cancer 25:1001–1011. https://doi.org/10.1007/s00520-016-3521-7CrossRefPubMed

10.

Bontempo PSM, Ciol MA, Menêses AG, Simino GPR, Ferreira EB, Reis PED (2021) Acute radiodermatitis in câncer patients: incidence and severity estimates. Ver Esc Enferm. USP 55:e3676. https://doi.org/10.1590/s1980-220x2019021703676CrossRef

11.

Bonomo P, Loi M, Desideri I et al (2017) Incidence of skin toxicity in squamous cell carcinoma of the head and neck treated with radiotherapy and cetuximab: A systematic review. Crit Rev Oncol Hematol 120:98–110. https://doi.org/10.1016/j.critrevonc.2017.10.011CrossRefPubMed

12.

Ginex PK, Backler C, Croson E et al (2020) Radiodermatitis in Patients With Cancer: Systematic Review and Meta-Analysis. Oncol Nurs Forum 47:E225–E236. https://doi.org/10.1188/20.onf.e225-e236CrossRefPubMed

13.

Robijns J, Laubach HJ (2018) Acute and chronic radiodermatitis clinical signs, pathophysiology, risk factors and management options. Journal of the Egyptian Women’s Dermatologic Society 15:2–9. https://doi.org/10.1097/01.EWX.0000529960.52517.4c

14.

Todorovic V, Prevc A, Zakelj MN et al (2019) Mechanisms of different response to ionizing irradiation in isogenic head and neck cancer cell lines. Radiat Oncol 2714:214. https://doi.org/10.1186/s13014-019-1418-6CrossRef

15.

Kole AJ, Kole L, Moran MS (2017) Acute radiation dermatitis in breast cancer patients: challenges and solutions. Breast Cancer-Targets. Therapy, vol 9, pp 313–323 https://doi.org/10.2147/BCTT.S109763CrossRef

16.

Costa CC, Lyra JS, Nakamura RA, Sousa CM (2019) Radiodermatitis: Analysis of Predictive Factors in Breast Cancer Patients. Rev bras Cancerol 65:e–05275. https://doi.org/10.32635/2176-9745.RBC.2019v65n1.275

17.

Andreassen CN, Dikomey E, Parliament M, West CM (2012) Will SNPs be useful predictors of normal tissue radiosensitivity in the future? Radiother Oncol 105:283–288. https://doi.org/10.1016/j.radonc.2012.11.003CrossRefPubMed

18.

Thiagarajan A, Iyer NG (2019) Genomics of radiation sensivity in squamous cell carcinomas. Pharmacogenomics 20:457–466. https://doi.org/10.2217/pgs-2018-0154CrossRefPubMed

19.

Morton LM, Ricks-Santi L, West CML, Rosenstein BS (2018) Radiogenomic Predictors of Adverse Effects following Charged Particle. Therapy Int J Part Ther 5:103–113. https://doi.org/10.14338/IJPT-18-00009.1CrossRefPubMed

20.

West C, Rosenstein BS, Alsner J et al (2010) Establishment of a Radiogenomics Consortium. Int J Radiat Oncol Biol Phys 76:1295–1296. https://doi.org/10.1016/j.ijrobp.2009.12.017CrossRefPubMed

21.

National Cancer Institute (2019) Epidemiology and Genomics Research Program. https://epi.grants.cancer.gov/radiogenomics/

22.

Story MD, Durante M (2018) Radiogenomics. Med Phys 45:1111–1112. https://doi.org/10.1002/mp.13064CrossRef

23.

Aguiar BRL, Ferreira EB, Normando AGC et al (2022) Single Nucleotide Polymorphisms to predict acute radiation dermatitis in breast cancer patients: A systematic review and meta-analysis. Crit Rev Oncol Hematol 173:103651. https://doi.org/10.1016/j.critrevonc.2022.103651CrossRefPubMed

24.

Ghazali N, Shaw RJ, Rogers SN, Risk JM (2012) Genomic determinants of normal tissue toxicity after radiotherapy for head and neck malignancy: a systematic review. Oral Oncol 48:1090–1100. https://doi.org/10.1016/j.oraloncology.2012.08.002CrossRefPubMed

25.

Zhao J, Zhi Z, Zhang M et al (2018) Predictive value of single nucleotide polymorphisms in XRCC1 for radiation-induced normal tissue toxicity. Onco Targets Ther 11:3901–3918CrossRefPubMedPubMedCentral

26.

Normando AGC, Rocha CL, Toledo IP et al (2017) Biomarkers in the assessment of oral mucositis in head and neck cancer patients: a systematic review and meta-analysis. Support Care Cancer 25:2969–2988. https://doi.org/10.1007/s00520-017-3783-8CrossRefPubMed

27.

Page MJ, Moher D, Bossuyt P et al (2020) PRISMA 2020. Explan Elabor (updated guidance and exemplars for reporting systematic reviews)

28.

Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A (2017) Rayyan—a web and mobile app for systematic reviews. Syst Rev 5:210CrossRef

29.

JBI (2017) Critical Appraisal Checklist for Cohort Studies. JBI. Available from: https://jbi.global/sites/default/files/2019-05/JBI_Critical_Appraisal-Checklist_for_Cohort_Studies2017_0.pdf

30.

Werbrouck J, De Ruyck K, Duprez F et al (2009) Acute normal tissue reactions in head-and-neck cancer patients treated with IMRT: influence of dose and association with genetic polymorphisms in DNA DSB repair genes. Int J Radiat Oncol Biol Phys 73:1187–1195. https://doi.org/10.1016/j.ijrobp.2008.08.073CrossRefPubMed

31.

Pratesi N, Mangoni M, Mancini I et al (2011) Association between single nucleotide polymorphisms in the XRCC1 and RAD51 genes and clinical radiosensitivity in head and neck cancer. Radiother Oncol 99:356–361. https://doi.org/10.1016/j.radonc.2011.05.062CrossRefPubMed

32.

Li H, You Y, Lin C et al (2013) XRCC1 codon 399Gln polymorphism is associated with radiotherapy-induced acute dermatitis and mucositis in nasopharyngeal carcinoma patients. Radiat Oncol 8:31. https://doi.org/10.1186/1748-717X-8-31CrossRefPubMedPubMedCentral

33.

Venkatesh GH, Manjunath VB, Mumbrekar KD et al (2014) Polymorphisms in radio-responsive genes and its association with acute toxicity among head and neck cancer patients. Plos One 9:e89079. https://doi.org/10.1371/journal.pone.0089079CrossRefPubMedPubMedCentral

34.

Yu J, Huang Y, Liu L et al (2016) Genetic polymorphisms of Wnt/β-catenin pathway genes are associated with the efficacy and toxicities of radiotherapy in patients with nasopharyngeal carcinoma. Oncotarget 7:82528–82537CrossRefPubMedPubMedCentral

35.

Zhai XM, Hu QC, Gu K, Wang JP, Zhang JN, Wu YW (2016) Significance of XRCC1 Codon399 polymorphisms in Chinese patients with locally advanced nasopharyngeal carcinoma treated with radiation therapy. Asia Pac J Clin Oncol 12:e125–e132. https://doi.org/10.1111/ajco.12117CrossRefPubMed

36.

Borchiellini D, Etienne-Grimaldi MC, Bensadoun RJ et al (2017) Candidate apoptotic and DNA repair gene approach confirms involvement of ERCC1, ERCC5, TP53 and MDM2 in radiation-induced toxicity in head and neck cancer. Oral Oncol 67:70–76. https://doi.org/10.1016/j.oraloncology.2017.02.003CrossRefPubMed

37.

Chen H, Wu M, Li G, Hua L, Chen S, Huang H (2017) Association between XRCC1 single-nucleotide polymorphism and acute radiation reaction in patients with nasopharyngeal carcinoma: a cohort study. Medicine (Baltimore) 96:e8202. https://doi.org/10.1097/md.0000000000008202

38.

Goutham HV, Mumbrekar KD, Hitendra N, Vadhiraja BM, Fernandes DJ, Rao SBS (2017) Genotype-phenotype association of TGF-β1 and GST with chemo-radiotherapy induced toxicity. Int J Radiat Res 15:15–23. https://doi.org/10.18869/acadpub.ijrr.15.1.15CrossRef

39.

Nanda SS, Gandhi AK, Rastogi M et al (2018) Evaluation of XRCC1 Gene Polymorphism as a Biomarker in Head and Neck Cancer Patients Undergoing Chemoradiation Therapy. Int J Radiat Oncol Biol Phys 101:593–601. https://doi.org/10.1016/j.ijrobp.2018.03.039CrossRefPubMed

40.

Duran G, Aguín S, Cruz R et al (2019) Association of GSTP1 and ERCC1 polymorphisms with toxicity in locally advanced head and neck cancer platinum-based chemoradiotherapy treatment. Head Neck 41:2704–2715. https://doi.org/10.1002/hed.25754CrossRefPubMed

41.

Raturi V, Hojo H, Bhatt MLB et al (2020) Prospective evaluation of XRCC‑1 Arg194Trp polymorphism as bio-predictor for clinical outcome in locally advanced laryngeal cancer undergoing cisplatin-based chemoradiation. Head Neck 42:1045–1056. https://doi.org/10.1002/hed.26083CrossRefPubMed

42.

Wang Y, Xiao F, Zhao Y et al (2022) A two-stage genome-wide association study to identify novel genetic loci associated with acute radiotherapy toxicity in nasopharyngeal carcinoma. Mol Cancer 21:169. https://doi.org/10.1186/s12943-022-01631-8CrossRefPubMedPubMedCentral

43.

Lee E, Eum SY, Slifer SH et al (2020) Association Between Polymorphisms in DNA Damage Repair Genes and Radiation Therapy-Induced Early Adverse Skin Reactions in a Breast Cancer Population: A Polygenic Risk Score Approach. Int J Radiat Oncol Biol Phys 106:948–957. https://doi.org/10.1016/j.ijrobp.2019.12.021CrossRefPubMed

44.

Gupta A, Mathew D, Bhat SA, Ghoshal S, Pal A (2021) Genetic Variants of DNA Repair Genes as Predictors of Radiation-Induced Subcutaneous Fibrosis in Oropharyngeal Carcinoma. Front Oncol 11:652049. https://doi.org/10.3389/fonc.2021.652049CrossRefPubMedPubMedCentral

45.

Fan J, Liu W, Zhang M, Xing C (2019) A literature review and systematic meta-analysis on XRCC3 Thr241Met polymorphism associating with susceptibility of oral cancer. Oncol Lett 18:3265–3273. https://doi.org/10.3892/ol.2019.10609CrossRefPubMedPubMedCentral

46.

Alkasaby MK, El-Fattah AAI, Ibrahim IH, El-Samie AHS (2020) Polymorphism of XRCC3 in Egyptian Breast Cancer Patients. Pharmgenomics Pers Med 13:273–282. https://doi.org/10.2147/pgpm.s260682CrossRefPubMedPubMedCentral

47.

Dashti S, Taherian-Esfahani Z, Keshtkar A, Ghafouri-Fard S (2019) Associations between XRCC3 Thr241Met polymorphisms and breast cancer risk: systematic-review and meta-analysis of 55 case-control studies. BMC Med Genet 20:79. https://doi.org/10.1186/s12881-019-0809-8CrossRefPubMedPubMedCentral

48.

Liu W, Ma S, Liang L, Kou Z, Zhang H, Yang J (2021) The association between XRCC3 rs1799794 polymorphism and cancer risk: a meta-analysis of 34 case-control studies. BMC Med Genomics 14:117. https://doi.org/10.1186/s12920-021-00965-4CrossRefPubMedPubMedCentral

49.

Guhlich M, Hubert L, Mergler CPN et al (2021) Identification of Risk Loci for Radiotoxicity in Prostate Cancer by Comprehensive Genotyping of TGFB1 and TGFBR1. Cancers (basel) 13:5585. https://doi.org/10.3390/cancers13215585CrossRefPubMed

50.

Alsbeih GA, El-Sebaie MM, Al-Rajhi NM et al (2008) Association between XRCC1 G399A Polymorphism and Late Complications to Radiotherapy in Saudi Head and Neck Cancer Patients. J Egypt Natl Canc Inst 20:302–308PubMed

51.

Kaur J, Sambyal V, Guleria K et al (2020) Association of XRCC1, XRCC2 and XRCC3 Gene Polymorphism with Esophageal Cancer Risk. Clin Exp Gastroenterol 13:73–86. https://doi.org/10.2147/ceg.s232961CrossRefPubMedPubMedCentral

52.

Nedooshan JJ, Yazdi MF, Neamatzadeh H, Shehneh MZ, Kargar S, Seddighi N (2017) Genetic Association of XRCC1 Gene rs1799782, rs25487 and rs25489 Polymorphisms with Risk of Thyroid Cancer: a Systematic Review and Meta-Analysis. Asian Pac J Cancer Prev 18:263–270. https://doi.org/10.22034/apjcp.2017.18.1.263CrossRefPubMedCentral

53.

Gupta A, Shah K, Oza MJ, Behl T (2019) Reactivation of p53 gene by MDM2 inhibitors: A novel therapy for cancer treatment. Biomed Pharmacother 109:484–492. https://doi.org/10.1016/j.biopha.2018.10.155CrossRefPubMed

54.

Lin J, Song T, Li C, Mao W (2020) GSK-3β in DNA repair, apoptosis, and resistance of chemotherapy, radiotherapy of cancer. Biochim Biophys Acta Mol Cell Res 1867:118659. https://doi.org/10.1016/j.bbamcr.2020.118659CrossRefPubMed

55.

Sirugo G, Williams SM, Tishkoff SA (2019) The missing diversity in human genetic studies. Cell 177:26–31. https://doi.org/10.1016/j.cell.2019.02.048CrossRefPubMedPubMedCentral

56.

Rosenstein BS (2017) Radiogenomics: Identification of Genomic Predictors for Radiation Toxicity. Semin Radiat Oncol 27:300–309. https://doi.org/10.1016/j.semradonc.2017.04.005CrossRefPubMedPubMedCentral

57.

Castro-Santos P, Verdugo RA, Alonso-Arias R et al (2020) Association analysis in a Latin American population revealed ethnic differences in rheumatoid arthritis-associated SNPs in Caucasian and Asian populations. Sci Rep 10:7879. https://doi.org/10.1038/s41598-020-64659-0CrossRefPubMedPubMedCentral

58.

Chugh R, Bisht YS, Nautiyal V, Jindal R (2021) Factors Influencing the Severity of Acute Radiation-Induced Skin and Mucosal Toxicity in Head and Neck Cancer. Cureus 13:e18147. https://doi.org/10.7759/cureus.18147CrossRefPubMedPubMedCentral

59.

Cavalcante LG, Domingues RAR, Junior BO, Fernandes MAR, Pessoa EC, Abbade LPF (2023) Incidence of radiodermatitis and factors associated with its severity in women with breast cancer: a cohort study. An Bras Dermatol S0365:186–191. https://doi.org/10.1016/j.abd.2023.01.004CrossRef

60.

Deng N, Zhou H, Fan H, Yuan Y (2017) Single nucleotide polymorphisms and cancer susceptibility. Oncotarget 8:110635–110649. https://doi.org/10.18632/oncotarget.22372CrossRefPubMedPubMedCentral

61.

Shah R, Sharma V, Bhat A et al (2020) MassARRAY analysis of twelve cancer related SNPs in esophageal squamous cell carcinoma in J&K, India. Bmc Cancer 20:497. https://doi.org/10.1186/s12885-020-06991-2CrossRefPubMedPubMedCentral

62.

Huang A, Glick SA (2017) Genetic susceptibility to cutaneous radiation injury. Arch Dermatol Res 1:10. https://doi.org/10.1007/s00403-016-1702-3CrossRef

63.

Aguiar BRL, Guerra ENS, Reis PED (2023) Radiogenomics: A Personalized Strategy for Predicting Radiation-Induced Dermatitis. IntechOpen https://doi.org/10.5772/intechopen.108745CrossRef

64.

Uffelmann E, Huang QQ, Munung NS et al (2021) Genome-wide association studies. Nat Rev Methods Primers 1:59. https://doi.org/10.1038/s43586-021-00056-9CrossRef

Titel: Potential Single Nucleotide Polymorphisms markers for radiation dermatitis in head and neck cancer patients: a meta-analysis
verfasst von: Beatriz Regina Lima Aguiar
Elaine Barros Ferreira
Ana Gabriela Costa Normando
Sabrina dos Santos Dias
Eliete Neves Silva Guerra
Paula Elaine Diniz Reis, PhD
Publikationsdatum: 26.04.2024
Verlag: Springer Berlin Heidelberg
Erschienen in: Strahlentherapie und Onkologie
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-024-02237-3

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Potential Single Nucleotide Polymorphisms markers for radiation dermatitis in head and neck cancer patients: a meta-analysis

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie